Features and Applications of Ehrlich Tumor Model in Cancer Studies: a Literature Review

Overview

Journal Transl Breast Cancer Res

Publisher AME Publishing Company

Date 2024 May 16

PMID 38751464

Authors

Debora Rasec Radulski

Maria Carolina Stipp

Claudia Martins Galindo

Alexandra Acco

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Breast cancer is the most prevalent cancer worldwide, responsible for a large number of deaths, especially among women. Therapeutic options for breast cancer include surgery, radiotherapy, chemotherapy, hormone therapy, and immunotherapy, but further studies of the pathogenesis of this disease and new treatments are still needed. and cancer models are important research tools. Murine Ehrlich tumors are one of these models, especially for hormone-positive breast cancer. The present narrative review discusses characteristics of the Ehrlich tumor model, laboratory manipulations of Ehrlich cells (ECs), and applications in pharmacological, pathological, and translational studies.

Methods: This review was based on scientific articles, books, and theses on Ehrlich tumors. We searched the PubMed, SciELO, Google Scholar, Google, and Clarivate databases.

Key Content And Findings: Hormone-positive ECs produce solid Ehrlich carcinoma (SEC) and ascitic Ehrlich carcinoma (AEC), with different features and applications. The presence of SEC or AEC induces systemic and immunological alterations that are similar to cancer in humans, what makes this model applicable to different studies in the cancer field.

Conclusions: Ehrlich tumors are a relevant tool for improving our understanding of the pathogenesis of breast cancer and investigating the tumor microenvironment, side effects of therapies, and new treatment options. Despite some limitations, such as the absence of an invasive phenotype to produce metastasis, both SEC and AEC are relevant in preclinical and translational studies of breast cancer.

Citing Articles

The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models.

Brauer J, Tumani M, Frey N, Lehmann L Basic Res Cardiol. 2024; 120(1):91-112.

PMID: 39621070 PMC: 11790711. DOI: 10.1007/s00395-024-01090-w.

Tumor alkalization therapy: misconception or good therapeutics perspective? - the case of malignant ascites.

Bogdanov A, Verlov N, Bogdanov A, Burdakov V, Semiletov V, Egorenkov V Front Oncol. 2024; 14:1342802.

PMID: 38390269 PMC: 10881708. DOI: 10.3389/fonc.2024.1342802.

References

Johansson A, Trewin C, Fredriksson I, Reinertsen K, Russnes H, Ursin G . In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Res. 2021; 23(1):17. PMC: 7852363. DOI: 10.1186/s13058-021-01393-z. View

de Lima L, Ganzella F, Cardoso G, Pires V, Chequin A, Santos G . l-carvone decreases breast cancer cells adhesion, migration, and invasion by suppressing FAK activation. Chem Biol Interact. 2023; 378:110480. DOI: 10.1016/j.cbi.2023.110480. View

Donenko F, Ziganshin R, Anisimova N, Voyushin K, Sitdikova S, Amandzholov B . Identification of serpin (alpha-1-antitrypsin) as serum growth inhibitory factor in murine ehrlich carcinoma by proteomics. Cancer Genomics Proteomics. 2010; 7(3):147-56. View

Mostafa A, Mohamed Abdelsalam S, S Sabbah W, Mekawey D . Mesenchymal Stem Cells Treatment Aggravates Tumor Growth Regardless Its Route of Administration: An In vivo Study. Asian Pac J Cancer Prev. 2022; 23(10):3309-3315. PMC: 9924341. DOI: 10.31557/APJCP.2022.23.10.3309. View

Ribba B, Holford N, Magni P, Troconiz I, Gueorguieva I, Girard P . A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e113. PMC: 4050233. DOI: 10.1038/psp.2014.12. View

Ibrahim H, Abdel Ghaffar F, El-Elaimy I, Gouida M, Abd El Latif H . Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice. Biomed Pharmacother. 2018; 106:43-49. DOI: 10.1016/j.biopha.2018.06.113. View

Morgulis M, Stankevicius D, Sa-Rocha L, Palermo-Neto J . Cohabitation with a sick cage mate: consequences on behavior and on ehrlich tumor growth. Neuroimmunomodulation. 2003; 11(1):49-57. DOI: 10.1159/000072969. View

Ruiz de Morales J, Velez D, Subiza J . Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony-stimulating factors and without engagement of host T cells. Exp Hematol. 2000; 27(12):1757-67. DOI: 10.1016/s0301-472x(99)00119-8. View

Yates J, Fairman D . How translational modeling in oncology needs to get the mechanism just right. Clin Transl Sci. 2021; 15(3):588-600. PMC: 8932697. DOI: 10.1111/cts.13183. View

10.

Badr El-Din N, Shabana S, Abdulmajeed B, Ghoneum M . A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation. BMC Complement Med Ther. 2020; 20(1):127. PMC: 7189677. DOI: 10.1186/s12906-020-02901-y. View

11.

. Cancer models for reverse and forward translation. Nat Cancer. 2022; 3(2):135. DOI: 10.1038/s43018-022-00346-5. View

12.

da Silva I, Veloso E, Goncalves I, Braga A, Lopes M, Cassali G . Qa-2 expression levels is related with tumor-infiltrating lymphocytes profile during solid Ehrlich tumor development. Biomed Pharmacother. 2017; 92:750-756. DOI: 10.1016/j.biopha.2017.05.135. View

13.

Morsi D, El-Nabi S, Elmaghraby M, Abu Ali O, Fayad E, Khalifa S . Anti-proliferative and immunomodulatory potencies of cinnamon oil on Ehrlich ascites carcinoma bearing mice. Sci Rep. 2022; 12(1):11839. PMC: 9276696. DOI: 10.1038/s41598-022-14770-1. View

14.

Alkreathy H, Alkhatib M, Al Musaddi S, Balamash K, Osman N, Ahmad A . Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma. Clin Exp Pharmacol Physiol. 2019; 46(5):496-505. DOI: 10.1111/1440-1681.13071. View

15.

Khan S, Hernandez-Villafuerte K, Hernandez D, Schlander M . Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach. Front Public Health. 2023; 10:946544. PMC: 9853539. DOI: 10.3389/fpubh.2022.946544. View

16.

Corso C, Stipp M, Adami E, da Silva L, Mariott M, de Andrade S . Salvia lachnostachys Benth has antitumor and chemopreventive effects against solid Ehrlich carcinoma. Mol Biol Rep. 2019; 46(5):4827-4841. DOI: 10.1007/s11033-019-04931-3. View

17.

Aysan E, Bayrak O, Aydemir E, Telci D, Sahin F, Yardimci C . Cancer preventive effects of whole cell type immunization against mice Ehrlich tumors. Asian Pac J Cancer Prev. 2013; 14(6):3515-9. DOI: 10.7314/apjcp.2013.14.6.3515. View

18.

Mandal D, Lahiry L, Bhattacharyya A, Bhattacharyya S, Sa G, Das T . Tumor-induced thymic involution via inhibition of IL-7R alpha and its JAK-STAT signaling pathway: protection by black tea. Int Immunopharmacol. 2006; 6(3):433-44. DOI: 10.1016/j.intimp.2005.09.005. View

19.

Gabai V, Mosina V, Budagova K, Kabakov A . Spontaneous overexpression of heat-shock proteins in Ehrlich ascites carcinoma cells during in vivo growth. Biochem Mol Biol Int. 1995; 35(1):95-102. View

20.

Kulagina T, Aripovsky A, Gapeyev A . Changes in fatty acid composition of thymus cells, liver, blood plasma, and muscle tissue in mice with solid Ehrlich carcinoma. Biochemistry (Mosc). 2012; 77(2):187-93. DOI: 10.1134/S0006297912020101. View